Abstract
Abstract A redox-sensitive beta-cyclodextrin nanoparticle (β-CD NP) system was prepared for the controlled release of curcumin (CUR), and its therapeutic efficacy on liver cancer was compared with that of CUR in vitro. 1-Dodecanethiol (DDT) was conjugated to per-6-thiol-β-CD by disulfide bond formation though an oxidation reaction (β-CD-ss-DDT). Rhodamine B (RhoB) was included into the β-CD-ss-DDT cavity by inclusion complex formation (β-CD-ss-DDT-ic-RhoB). CUR was encapsulated into β-CD-ss-DDT-ic-RhoB aggregates by self-assembly through dialysis method. The composition, morphology, size distribution and zeta potential of β-CD-ss-DDT-ic-RhoB NPs were characterized by proton nuclear magnetic resonance (1H NMR), Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM) and dynamic light scattering (DLS), respectively. It was found that CUR was released from β-CD-ss-DDT-ic-RhoB/CUR NPs due to the dissociation of β-CD-ss-DDT through a reduction reaction. β-CD-ss-DDT-ic-RhoB/CUR NPs had a higher cellular uptake ratio and a greater anticancer effect on mouse hepatoma Hepa 1-6 cells than CUR, mainly attributed to the improved water-solubility of CUR after encapsulating it in the NPs. Our findings suggest that β-CD-ss-DDT-ic-RhoB NPs can be used as nanocarriers for delivering CUR into cancer cells, thereby serving as a clinical therapeutic agent for liver cancer treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
